Circassia’s cat allergy treatment shows sustained symptom improvement

26-Feb-2013 - Imperial Innovations Group plc announced that portfolio company Circassia has seen strong results from its follow up phase II clinical trial. Patients saw a sustained improvement of their cat allergy symptoms two years after they started a four-dose, 12 week course of Circassia’s ToleroMune® cat ...

Circassia initiates phase III trial for cat allergy treatment

09-Oct-2012 - Imperial Innovations Group plc announced that its portfolio company, Circassia has initiated a pivotal large-scale phase III clinical study of its ToleroMune® cat allergy treatment. Circassia’s phase III multinational study will test safety and efficacy of the ToleroMune® treatment in ...

Circassia ragweed vaccine achieves phase II clinical development milestone

09-Mar-2012 - Imperial Innovations Group plc announces that portfolio company Circassia has successfully completed a large-scale phase II clinical study of its ToleroMune® ragweed allergy treatment. Ragweed pollen is one of the main allergens responsible for hayfever in the US and its prevalence is increasing ...

Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies

Circassia also advances Phase III Plans for cat Allergy T-Cell Vaccine

04-Oct-2010 - Circassia Ltd announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines. In recent weeks, Circassia has initiated phase II clinical testing of its grass allergy (hayfever) therapy, begun the final stage of phase II testing with its ragweed ...

Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies

21-Jan-2010 - Circassia Ltd announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical ...

Circassia Achieves Successful Phase II Clinical Results With ToleroMune Anti-Allergy Technology

15-Sep-2008 - Circassia Ltd announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and ...

Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology

28-Feb-2008 - Circassia Ltd announced that it has initiated a phase II clinical study with its anti-allergy technology, ToleroMune. Circassia is conducting the study in the field of cat-dander allergy, and aims to complete the trial in the coming months. This clinical study builds on the results of a previous ...

Circassia Appoints Sir Richard Sykes as Chairman of the Board

06-Jul-2007 - Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced the appointment of Sir Richard Sykes as Chairman of the Board. Sir Richard succeeds Charles Swingland who held the post of Executive Chairman following the establishment of the business ...